Celldex Therapeutics, Inc (CLDX) is a publicly traded Healthcare sector company. As of May 20, 2026, CLDX trades at $31.08 with a market cap of $2.37B and a P/E ratio of -7.83. CLDX moved +2.54% today. Year to date, CLDX is +20.70%; over the trailing twelve months it is +50.81%. Its 52-week range spans $14.40 to $35.79. Analyst consensus is strong buy with an average price target of $56.73. Rallies surfaces CLDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Celldex Therapeutics, Inc (CLDX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. CLDX moved +2.54% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $31.08 |
| Market Cap | $2.37B |
| P/E Ratio | -7.83 |
| EPS | $-3.90 |
| Dividend Yield | 0.00% |
| 52-Week High | $35.79 |
| 52-Week Low | $14.40 |
| Volume | 645.12K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.54M |
| Net Income | $-258.76M |
| Gross Margin | 87.06% |
12 analysts cover CLDX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $56.73.